Citalopram therapy for depression: A review of 10 years of european experience and data from U.S. clinical trials

Journal of Clinical Psychiatry

Volumn 61, Issue 12, 2000, Pages 896-908

  Keller, M B ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BISOPROLOL; BISOPROLOL FUMARATE; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DIAZEPAM; DIGOXIN; DURATUSS; FLECAINIDE; FLECAINIDE ACETATE; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; HALOPERIDOL; HYDROCODONE; IMIPRAMINE; MAPROTILINE; METOPROLOL; MIANSERIN; MORPHINE; MORPHINE SULFATE; NORTRIPTYLINE; OXAZEPAM; PAROXETINE; PERPHENAZINE; PLACEBO; PROPAFENONE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TEMAZEPAM; TETRACYCLIC ANTIDEPRESSANT AGENT; THIORIDAZINE; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; WARFARIN;

ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; META ANALYSIS; PANIC; PRIORITY JOURNAL; RECURRENT DISEASE; SIDE EFFECT; UNITED STATES;

EID: 0034531061     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v61n1202     Document Type: Article

References (82)

1. Efficacy in long-term treatment of depression
2. The pharmacology of citalopram
3. Citalopram: Pharmacological profile of a specific serotonin up-take inhibitor with antidepressant activity
4. Clinical pharmacokinetics of selective serotonin reuptake inhibitors
5. The pharmacokinetics of citalopram
6. Dose-dependent inhibition of CYP1A2, CYP2C19, and CYP2D6 by citalopram, fluoxetine, fluvoxamine, and paroxetine
7. Drug interactions with newer antidepressants: Role of human cytochromes P450
8. Citalopram and desmethylcitalopram in vitro: Human cytochromes mediating transformation and cytochrome inhibitory effects
9. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia
10. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia
11. Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice
12. The effectiveness of citalopram in the prevention of depression recurrence in elderly patients
13. The antidepressant efficacy of citalopram
14. Citalopram in the treatment of depression
15. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate to severe depression
16. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline
17. Dose response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression
18. The optimal dosing regimen for citalopram: A meta-analysis of nine placebo-controlled studies
19. Citalopram in depression: Meta-analysis of intended and unintended effects
20. Meta-analysis of placebo-controlled trials of citalopram in the treatment of depression
21. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression
22. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: A placebo-controlled 6 month study
23. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression
24. Prevention of depression recurrence with citalopram: Results from a double-blind, placebo-controlled trial
25. A comparison of the antidepressant action of citalopram and amitriptyline
26. A double-blind comparison of citalopram (Lu 10-171) and amitriptyline in depressed patients
27. Citalopram: Clinical effect profile in comparison with clomipramine: A controlled multicenter study
28. Paroxetine a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study
29. Treatment of severe depression with the selective serotonin reuptake inhibitors
30. Selective serotonin reuptake inhibitor efficacy in severe and melancholic depression
31. Citalopram and imipramine in the treatment of depressive patients in general practice: A Nordic multicentre clinical study
32. A double-blind comparative clinical trial of citalopram vs maprotiline in hospitalized depressed patients
33. Citalopram versus maprotiline: A controlled, clinical multicentre trial in depressed patients
34. Citalopram versus mianserin: A controlled, double-blind trial in depressed patients
35. Clinical multi-centre study of citalopram compared double-blindly with mianserin in depressed patients in Finland
36. A randomised, double blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia
37. Citalopram versus fluoxetine: A double blind, controlled, multicentre, phase llI trial in patients with unipolar major depression treated in general practice
38. Citalopram and fluoxetine in major depression: Comparison of two clinical trials in a psychiatrist setting and in general practice
39. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice
40. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: A double-blind, multicentre study
41. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder
42. The effect of citalopram in panic disorder
43. SSRIs and ejaculation: A double-blind, randomized, comparative fixed-dose study with paroxetine and citalopram
44. Effect of SSRI antidepressants on ejaculation: A double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline
45. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal
46. Physiological correlates of SSRI withdrawal: Evidence from a controlled, randomized trial of fluoxetine, sertraline, and paroxetine
47. Effects of abrupt discontinuation of citalopram
48. An assessment of selective serotonin reuptake inhibitor discontinuation effects associated with citalopram
49. Adverse event profile of citalopram in the elderly
50. The safety and tolerability of citalopram
51. Orthostatic side effects of clomipramine and citalopram during treatment for depression
52. The effects of citalopram in single and repeated doses and with alcohol on physiological and psychological measures in healthy subjects
53. Citalopram compared to dothiepin and placebo: Effects on cognitive function and psychomotor performance
54. The unexpected preclinical finding: Elucidation of dog toxicity citalopram
55. Cardiac safety of citalopram: Pro-spective trials and retrospective analyses
56. Antidepressant drugs and the cardiovascular system: A comparison of tricylics and selective serotonin reuptake inhibitors and their relevance for the treatment of psychiatric patients with cardiovascular problems
57. SSRI safety in overdose
58. Citalopram overdose: Review of cases treated in Swedish hospitals
59. Fatal overdose with citalopram
60. Report of a fluoxetine fatality
61. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients
62. Effects of SSRIs on CYP2D6-mediated metabolism of metoprolol
63. Citalopram: Interaction studies with levomepromazine, imipramine, and lithium
64. Lack of effect of citalopram on the steady state pharmacokinetics of carbamazepine in healthy male subjects
65. Lack of interaction between citalopram and the CYP3A4 substrate triazolam
66. Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin
67. Lack of citalopram effect on oral digoxin pharmacokinetics
68. Citalopram: A review of its pharmacology, clinical efficacy and tolerability in the treatment of depression
69. Citalopram dosing of depressed patients by US psychiatrists
70. Steady-state pharmacokinetics of citalopram in young and elderly subjects
71. Update: Clinically significant cytochrome P-450 drug interactions
72. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: A Nordic multicentre study
73. Long-term treatment of elderly individuals with emotional disturbances: An open study with citalopram
74. An open pilot study of citalopram for behavioral disturbances of dementia: Plasma levels and real time observations
75. Publication bias and clinical trials
76. Factors influencing publication of research results: Follow-up of applications submitted to two institutional review boards
77. Effect of the statistical significance of results oh the time to completion and publication of randomized efficacy trials
78. Publication bias: Evidence of delayed publication in a cohort study of clinical research projects
79. Publication bias in clinical research
80. Publication bias: The triumph of hope over experience